×
About 15,803 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,184 results

Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair...
https://doi.org/10.1001/jamadermatol.2022.4867
JAMA Dermatology; Drake L, Reyes-Hadsall S et. al.

Dec 1st, 2022 - Despite the widespread use of nutritional supplements and dietary interventions for treating hair loss, the safety and effectiveness of available products remain unclear. To evaluate and compile the findings of all dietary and nutritional interven...

Efficacy of Jessener solution versus intralesional steroid in treatment of alopecia are...
https://doi.org/10.1111/jocd.15546
Journal of Cosmetic Dermatology; Elshahid AR, Kadah AS et. al.

Dec 1st, 2022 - Alopecia areata is an autoimmune condition that causes non-scarring hair loss. To date, there is no single cure and treatment remains challenging. To evaluate the efficacy of Jessener solution versus intralesional steroid in treatment of Alopecia ...

Iron Screening in Alopecia Areata Patients May Catch Hereditary Hemochromatosis Early.
https://doi.org/10.12788/cutis.0650
Cutis Leung B, Lindley L et. al.

Nov 30th, 2022 - Hereditary hemochromatosis (HHC), a disorder of iron overload, presents with clinical phenotypic heterogeneity. Complications can be mitigated with early intervention. The association between HHC and alopecia areata (AA) is unknown. We report 4 pa...

Merkel cell number and distribution, and CD200 expression in patients with lichen plano...
https://doi.org/10.1111/cup.14303
Journal of Cutaneous Pathology; Erbağcı E, Karaduman A et. al.

Nov 30th, 2022 - Immune mechanisms are considered to be responsible for the pathogenesis of cicatricial alopecia in lichen planopilaris (LPP) and discoid lupus erythematosus (DLE) diseases. CD200 has an immunomodulatory function in hair follicles. The functions of...

A narrative review on subcutaneous injection components used for alopecia.
https://doi.org/10.1111/jocd.15522
Journal of Cosmetic Dermatology; Kim JH

Nov 29th, 2022 - Studies reporting the development and effectiveness of topical agents for alopecia are available. However, it was difficult to demonstrate a direct advantage of subcutaneous injection rather than topical application. Since existing articles lack i...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  428 results see all →

Clinicaltrials.gov  442 results

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Oct 14th, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Comparing Aloe Vera Gel and Rosemary Oil in Pressure Injury Prevention
https://clinicaltrials.gov/ct2/show/NCT05578638

Oct 13th, 2022 - Aloe Vera is medicinal plant that has been used to treat skin problems since 1500 BC Many studies have shown that using Aloe Vera to treat various wounds such as psoriasis, mouth ulcers, diabetic ulcers herpes and bed sores has had positive effect...

Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05414266

Oct 13th, 2022 - The purpose of this study is to evaluate the efficacy and tolerability of squaric acid dibutylester (SADBE) in children and adolescents with alopecia areata (AA) and to evaluate effect of squaric acid dibutyl ester on patient-centered outcomes and...

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
https://clinicaltrials.gov/ct2/show/NCT05456087

Oct 5th, 2022 - Adult volunteers aged 22-45 years presenting with mild to moderate patterned hair loss will be screened for participation. Twenty subjects (10 males and 10 females) meeting the inclusion/exclusion criteria will be recruited to participate. Prior t...

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT02797470

Oct 5th, 2022 - PRIMARY OBJECTIVE: I. Safety, defined as timely engraftment (the collective establishment of a persistent absolute neutrophil count of at least 500 cells/mm^3 and platelet count of 20,000 cells/mm^3 without transfusion for 3 consecutive measuremen...

see more →

News  1,240 results

Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma
https://www.onclive.com/view/belantamab-mafodotin-to-be-withdrawn-from-us-market-for-relapsed-refractory-myeloma

Nov 22nd, 2022 - GlaxoSmithKline (GSK) plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf (Blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at le...

EMA Recommends Limiting the Indications for JAK Inhibitors
https://www.medscape.com/viewarticle/984399

Nov 21st, 2022 - AMSTERDAM — In an effort to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended limiting the indicat...

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC
https://www.onclive.com/view/frontline-eganelisib-triplet-provides-potential-long-term-pfs-benefit-in-metastatic-tnbc

Nov 15th, 2022 - The addition of eganelisib (IPI-549) to atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) demonstrated evidence of a long-term progression-free survival (PFS) benefit when used as first-line treatment in patients with metastatic triple-negati...

Immunotherapy and You: Gynecologic Treatment Efficacy From a Patient’s Perspective
https://www.onclive.com/view/immunotherapy-and-you-gynecologic-treatment-efficacy-from-a-patient-s-perspective

Nov 10th, 2022 - In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, of the Division of Gynecologic Oncology, Allegheny Health Network, and assistant professor of OBGYN at Drexel University, and Ali Amjad, MD, medical hematologic oncologi...

Belantamab Mafodotin Fails to Meet PFS End Point in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/belantamab-mafodotin-fails-to-meet-pfs-end-point-in-relapsed-refractory-multiple-myeloma

Nov 7th, 2022 - Belantamab mafodotin-blmf (Blenrep) did not generate a progression-free survival (PFS) benefit vs the combination of pomalidomide (Pomalyst) plus low-dose dexamethasone, failing to meet the primary end point of the phase 3 DREAMM-3 trial (NCT04162...

see more →

Patient Education  24 results see all →